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Background: Antiviral and immune-modulating properties 
of low-molecular-weight heparin (LMWH) against Coro-
naviridae have been reported by in vitro studies, but no in 
vivo evidence is yet available. We sought to know whether 
the timing of prophylactic doses of LMWH during the 
course of COVID-19 may affect the time to SARS-CoV-2 
nasal-oropharyngeal swab negativization.
Methods: Retrospective monocentric cross-sectional 
study on patients requiring sub-intensive ward admis-
sion due to first SARS-CoV-2 infection and undergo-
ing early (EH; within 7 days from COVID-19 signs and 
symptoms onset) versus delayed prophylactic LMWH (DH; 
after 7 days). SARS-CoV-2 RNA was measured by reverse 
transcription real-time PCR according to scheduled time 
points: first swab after 2 weeks from COVID-19 onset, 
then at 1-week intervals until negativity.
Results: Time to SARS-CoV-2 swab negativity was shorter 
in EH (38 patients) compared with DH (55 patients): 22 
versus 37 days (P=0.004). The number of confirmative 
negative swabs in EH was significantly higher compared 
with DH at week 2 (21.1% versus 3.6%; P=0.017) and 4 
(60.0% versus 19.6%; P<0.001). At univariate, EH dif-
fered from DH for several disease severity and clinical 
management parameters. Nevertheless, after accounting 
for the differences, Cox regression showed early LMWH 
administration (hazard ratio [HR] 2.91 [1.51, 5.63]; 
P=0.002) and higher lymphocytes nadir (HR 1.04 [1.01, 
1.08]; P=0.020) as predictors of shorter time to swab 
negativity.
Conclusions: This potential antiviral and/or immune-
modulating activity of LMWH needs further in vivo con-
firmations by randomized controlled trials.
After almost 1 year from the first COVID-19 cases, 
deaths are still increasing, while the number of drugs 
with proven benefits is not. As long as the results of 
randomized clinical trials are not available, the debate 
surrounding the true effectiveness of several drugs, 
such as of azithromycin or hydroxychloroquine in 
SARS-CoV-2 infection will likely continue [1]. From 
this chaotic scenario, heparin is emerging as one of the 
few drugs with a proven positive impact upon the clini-
cal outcomes of patients suffering from COVID-19. 
Indeed, with undoubted anticoagulant activity, hepa-
rin use has been associated with a reduced mortal-
ity among patients at elevated risk of the thrombotic 
complications of this ‘viral coagulopathy’ [2,3]. 
Nevertheless, based on in  vitro data, different other 
activities have been allegedly postulated for heparins: 
antiarrhythmic, anti-inflammatory, immune-modulat-
ing and antiviral [4–7]. Regarding the latter, heparins 
could potentially reduce virion adhesion to host cells 
through several mechanisms (Figure 1): by destabiliz-
ing the bond between ACE2 receptor and the receptor-
binding-domain of SARS-CoV-2, by inhibiting several 
proteases that cleave SARS-CoV-2 spike proteins, 
and by competing with cell-surface heparan sulphate, 
essential for the viral docking to human cells [4,5,7]. 
Thereby, heparin may eventually hamper SARS-CoV-2 
infectivity and replication, as already hypothesized 
and observed in preliminary studies on cell cultures 
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exposed to other human coronaviruses [4,8]. Consid-
ering the physio-pathological dynamics of COVID-19, 
heparins may express these further advantages more 
effectively when administered early in the disease 
course [6]. Notwithstanding, type and doses of hep-
arins aimed at exploiting these possibilities are once 
again a matter of debate, as these properties probably 
related to the molecular structure of different heparins 
and other factors [7].
Aim of our study was to assess whether the tim-
ing of administration of prophylactic low-molecular-
weight heparins (LMWH) dose during the course of 
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Figure 1. Potential antiviral properties of low-molecular-weight heparins in SARS-CoV-2 infection
LMWH, low-molecular-weight heparin. 
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COVID-19 may affect the time to SARS-CoV-2 nasal-
oropharyngeal swab (NPs) negativization.
Methods
We retrospectively reviewed data from SARS-CoV-2- 
positive patients admitted to the Infectious Diseases wards 
(Amedeo di Savoia Hospital, Turin, Italy) between March 
and June 2020 that consented to data collection and that 
underwent prophylactic doses of LMWH adjusted for 
renal function and body weight until discharge/death, as 
previously detailed [3]. We excluded patients with previ-
ous hospitalization for COVID-19 in other wards before 
referral to ours or previously diagnosed with COVID-19 
that required further admissions due to clinical or viro-
logical SARS-CoV-2 relapses. SARS-CoV-2 NPs were 
tested by an in-house reverse transcription real-time PCR 
according to Corman et al. [9] with the first NPs sched-
uled after 2 weeks (±3 days) from COVID-19 onset, then 
at 1-week intervals (±3 days) until swab negativity (two 
negative NPs 24 h apart). Anti-SARS-CoV-2 S1/S2 IgG 
were measured by chemiluminescence (Diasorin, Salug-
gia, Italy) from 1 May and clinically driven schedules. 
Patients were classified into early LMWH administration 
(EH; within 7 days from COVID-19 signs and symptoms 
onset) versus delayed (DH; after 7 days). Mann–Whit-
ney, Kruskal–Wallis, Spearman’s correlation and sur-
vival analyses were performed (SPSSv26; IBM, Armonk, 
NY, USA). Variables showing univariate P≤0.10 were 
included in the Cox regression (entering method). Con-
tinuous variables are presented as median (interquartile 
range), while categorical data as absolute number (pro-
portion). The protocol conforms to Helsinki Declaration 
and was approved by ‘Città della Salute e della Scienza’ 
Ethics Committee (protocol 00304/2020).
Results
A total of 93 patients were included. 67.7% were male. 
The median age, the ratio of arterial oxygen partial 
pressure (mmHg) to fractional inspired oxygen (P/F 
ratio) nadir, serum creatinine nadir and platelet count 
nadir were 68 years (60–80), 225 (127–321), 1.02 
mg/dl (0.88–1.24) and 166,000 cells/mm3 (133,500–
213,250), respectively. 24 patients both underwent 
CPAP/reservoir and Venturi mask, 5 intubation, while 
the others were on low-flow wall-oxygen (24) and 
ambient air (16). 11 deaths occurred, of which 8 were 
COVID-19-related. The median time from COVID-19 
signs and symptoms onset to hospitalization, prophy-
lactic LMWH start, first positive serology (available for 
45 patients, 48.4%) and SARS-CoV-2 NPs negativity 
were 6 (2–9), 8 (4–12), 32 (15–45) and 33 days (21–41; 
4 patients were still swab-positive when writing this 
report and 8 died swab-positive), respectively.
Compared with DH (55), EH (38) showed shorter 
times from COVID-19 onset to hospitalization (3 ver-
sus 9 days; P<0.001), to NPs negativity (22 versus 37 
days; P=0.004) and to the first positive serology (16 
versus 35 days; P=0.043; Table 1). As shown in Table 1, 
EH were characterized by lower first-determination of 
anti-S1/S2 IgG titres, higher nadir of lymphocytes and 
of P/F ratio and by a larger proportion of patients that 
underwent remdesivir and a smaller one that required 
ventilation supports other than none or low-flow wall-
oxygen (44.7% versus 65.4%; P=0.048), anti-inflam-
matory drugs and corticosteroids. At week 2 and 4 
from COVID-19 onset, higher proportions of patients 
in EH were confirmed swab-negative: 21.1% versus 
3.6% at week 2 (odds ratio [OR] 0.14 [0.028, 0.71]; 
P=0.017) and 60.0% versus 19.6% at week 4 (OR 0.16 
[0.062, 0.43]; P<0.001; Table 1). In accordance with 
the evolution of clinical practice during the pandemic, 
patients admitted in May–June were more likely to 
belong to EH compared with those admitted previously 
(63.4% versus 36.6%; P<0.001). No other significant 
differences were observed (Table 1).
The time from COVID-19 onset to NPs negativity 
correlated with that to LMWH start (r=0.48, P<0.001) 
and to the first positive serology (r=0.66, P<0.001), 
and with the lymphocytes nadir during the hospitaliza-
tion (absolute number; r=-0.28, P=0.012; percentage: 
r=-0.31, P=0.006).
Log-rank analysis was performed confirming a signif-
icant difference in the time to NPs negativity in favour 
of EH compared to DH (Mantel–Cox P<0.001). The 
Kaplan–Meier curve is shown in Figure 2. At the Cox 
proportional-hazards model (c2 P=0.007) that included 
age, most intensive type of oxygen support, anti-inflam-
matory, remdesivir and corticosteroid use, admission 
period (early versus late pandemic) and time to hos-
pitalization, lymphocytes nadir (HR 1.04 [1.01, 1.08]; 
P=0.020) and LMWH administration within the first 
week from COVID-19 onset (HR 2.91 [1.51, 5.63]; 
P=0.002) independently associated with shorter times 
to SARS-CoV-2 NPs negativity (Table 2). The corre-
sponding regression curve is shown in Figure 2.
Discussion
We observed a significant shorter time to in SARS-
CoV-2 swab negativity (15 days) among patients start-
ing prophylactic doses of LMWH within 7 days from 
COVID-19 onset compared with those starting LMWH 
later during the disease course, with about 5 and 3 times 
more confirmative negative NPs in EH compared with 
DH at week 2 and 4, respectively. Even after accounting 
for other determinants potentially able to affect viral 
shedding from the upper respiratory airways, SARS-
CoV-2 NPs were almost 3 times more likely to become 
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negative among patients that started LMWH within the 
first week from COVID-19 onset compared with those 
that received LMWH later on.
To the best of our knowledge, this finding may rep-
resent the first in vivo evidence of a potential antivi-
ral and/or immune-modulating activity of LMWH in 
 EH (n=38) DH (n=55) P-value
Baseline characteristics   
Age, years 66 (57–82) 68 (59–79) 0.87
Male, n (%) 26 (68.4) 37 (67.3) 0.86
Admission date   <0.001
March – Mid-April (early epidemic), n (%) 12 (31.6) 40 (72.7) 
Mid-April – June (late epidemic), n (%) 26 (68.4) 15 (27.3) 
Time from COVID-19 onset to hospitalization, days 3 (1–5) 9 (6–12) <0.001
Time from COVID-19 onset to COVID-19 diagnosis, days 2 (0–4) 7 (4–11) <0.001
Treatment characteristics 
Most intensive ventilation support   0.012
None, n (%) 8 (21.1) 8 (14.5) 
Low-flow wall oxygen, n (%) 13 (34.2) 11 (20.0) 
Venturi mask, n (%) 11 (28.9) 13 (23.6) 
CPAP - reservoir, n (%) 6 (15.8) 18 (32.7) 
Intubation, n (%) 0 (0) 5 (9.1) 
Treatment   
Corticosteroids, n (%) 12 (31.6) 29 (52.7) 0.045
Antiviralsa, n (%) 27 (71.1) 42 (76.4) 0.57
Remdesivir only, n (%) 11 (28.9) 4 (7.3) 0.005
Anti-inflammatory drugsb, n (%) 8 (21.1) 29 (52.7) 0.002
Type of LMWH   0.84
Enoxaparin, n (%) 35 (92.1) 50 (90.9) 
Parnaparin, n (%) 3 (7.9) 5 (9.1) 
LMWH starting dose   
Enoxaparin, IU/day 6,000 (6,000–6,000) 4,000 (4,000–4,000) 0.94
Parnaparin, IU/day 4,000 (4,000–4,000) 5,000 (4,000–5,000) 0.43
Time from COVID-19 onset to LMWH start, days 3 (2–4) 11 (8–16) <0.001
Outcomes 
Deaths   
Overall-causes deaths, n (%) 4 (10.5) 7 (12.7) 0.75
COVID-19-related deaths, n (%) 2 (5.3) 6 (10.9) 0.34
Time from COVID-19 onset to swab negativity, days 22 (14–35) 37 (30–48) 0.004
Confirmative negative swab   
II week from COVID-19 onset, n (%) 8 (21.1) 2 (3.6) 0.017
IV week from COVID-19 onset, n (%) 21/35 (60.0) 10/51 (19.6) <0.001
Time from COVID-19 onset to serology positivity, days 16 (9–36) 35 (28–54) 0.043
Anti-S1/S2 IgG titres, U/ml 26 (0–66) 66 (40–107) 0.035
Worst serum creatinine, mg/dl 1.0 (0.8–1.2) 1.0 (0.8–1.4) 0.83
Worst IL-6, pg/ml 55 (23–182) 82 (34–198) 0.31
Worst D-dimer, ng/ml 658 (337–1,332) 903 (414–3,576) 0.33
Worst ferritin, ng/ml 780 (184–1,052) 852 (441–1,613) 0.73
Worst fibrinogen, mg/dl 623 (519–687) 601 (505–769) 0.76
Lymphocytes nadir   
Percentage 11.9 (8.4–18.1) 7.7 (4.0–15.1) 0.019
Absolute number, cells/mm3 795 (628–1,093) 605 (440–908) 0.011
P/F ratio nadir 270 (190–350) 178 (122–311) 0.023
Platelet count nadir, ×103 cells/mm3 180 (140–210) 154 (115–218) 0.29
Table 1. Comparison of demographic, clinical, laboratory and viro-immunological features of patients starting low-molecular-
weight heparin within versus after 7 days from COVID-19 onset
Continuous variables are presented as median (IQR). aAntivirals included: 27 lopinavir/ritonavir, 59 hydroxychloroquine and 15 remdesivir. bAnti-inflammatory drugs 
included: 1 ruxolitinib, 2 imatinib, 35 tocilizumab. COVID-19, novel coronavirus 2019 disease; CPAP, continuous positive airway pressure support; DH, delayed low-
molecular-weight heparin administration group; EH, early low-molecular-weight heparin administration group; IL-6, interleukin 6; LMWH, low-molecular-weight heparins; 
P/F ratio, arterial pO2/fraction (%) of inspired oxygen ratio. 
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COVID-19. However, this putative effect warrants 
further validation against an untreated control group. 
Moreover, much has been affirmed and then retracted 
about this infection. Firstly, we have not taken into 
account the amount of viral load at the diagnostic swab 
so that we were not able to adjust our results for viral 
kinetics. Age has been linked to the amount of virus 
in the upper respiratory airways and was therefore 
included in our model to partially and indirectly adjust 
for this factor [10]. Secondly, corticosteroid type, spe-
cific doses and administration timing were extremely 
heterogeneous during the first COVID-19 wave and 
not taken into account in our analysis as well as pos-
sible delays in other drug administration; all of these 
factors may affect viral shedding dynamics [11–13]; 
further studies are required to provide data on how to 
interpret the effect of steroids upon SARS-CoV-2 kinet-
ics. Furthermore, serology was available in 45 patients 
only, all belonging to the later phase of the pandemic. 
Analyses including serological data were performed to 
assess possible confounding, but the lower IgG titres 
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Figure 2. Difference in time to SARS-CoV-2 negativity at nasal-pharyngeal swab between early and delayed low-molecular-
weight heparin group 
(A) Kaplan-Meier and (B) Cox proportional hazards regression curves. The Cox proportional hazards model included age, most intensive oxygen support required, 
anti-inflammatory drugs use, remdesivir use, corticosteroids use, hospitalization in the early versus late pandemic period, time to hospitalization from COVID-19 onset, 
lymphocytes nadir during hospitalization and LMWH administration within the first week from COVID-19 onset. Continuous lines represent the early low-molecular-
weight heparin administration (EH) group; dotted lines represent the delayed low-molecular-weight heparin administration (DH) group.
Covariates HR (95% CI) P-value
Age 0.97 (0.95, 0.99) 0.029
Most intensive oxygen support  
None – 0.669
Low-flow wall oxygen 1.27 (0.57, 2.82) 0.556
Venturi mask 1.02 (0.42, 2.47) 0.971
CPAP - reservoir 1.37 (0.56, 3.37) 0.487
Intubation 0.60 (0.17, 2.09) 0.427
Anti-inflammatory drugsa 1.48 (0.78, 2.83) 0.234
Corticosteroids 1.26 (0.67, 2.34) 0.473
Remdesivir 0.46 (0.17, 1.23) 0.121
Time from COVID-19 onset 1.02 (0.97, 1.07) 0.459
to hospitalization
Admission period 1.39 (0.73, 2.67) 0.316
(early versus late pandemic)
Early LMWH administration 2.91 (1.51, 5.63) 0.002
Lymphocyte nadir, % 1.04 (1.01, 1.08) 0.020
Table 2. Cox proportional hazards model for SARS-CoV-2 
nasal-pharyngeal swab negativity
aAnti-inflammatory drugs included: 1 ruxolitinib, 2 imatinib, 35 tocilizumab. 
COVID-19, 2019 novel coronavirus disease; CPAP, continuous positive airways 
pressure; LMWH, low-molecular-weight heparin.  
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test, differently from the scheduled NPs, so that, while 
our preliminary results may point towards a potential 
positive effect of LMWH also upon anti-SARS-CoV-2 
neutralizing antibodies development, tailored prospec-
tive studies should address the phenomenon.
An extensive and deeper knowledge in SARS-CoV-2 
life cycle and immunity, as well as in treatment-, labora-
tory- and host-related factors able to affect NPs results 
are required to confirm the validity of our model firstly 
and eventually of our observation.
The implications and confirmation of our prelimi-
nary results could potentially help at reaching a con-
sensus on several unanswered questions regarding the 
management of new COVID-19 patients while waiting 
for the results of several ongoing randomized clinical 
trials. First, balancing benefits and risks, home LMWH 
prescription could reduce infectivity and transmission 
within households, one of the settings at the highest 
risk of SARS-CoV-2 transmission [13,14], and could 
potentially prevent clinical deteriorations regardless 
of antithrombotic effects among SARS-CoV-2-positive 
patients not requiring hospitalization [15,16]. How-
ever, infectivity of patients after about 10 days from 
the onset of mild to moderate COVID-19 has been 
recently questioned [17,18], leaving uncertain the pos-
sible favourable impact of LMWH on the transmission 
containment. Whether viral inoculum predict disease 
severity is also a matter of current debate [19,20]. If 
this association was definitively confirmed and LMWH 
proved to accelerate viral load decay from the upper 
respiratory airways, LMWH use could impact on both 
disease transmissibility and severity among secondary 
cases. On the other hand, LMWH continuation could 
be indicated for hospital-discharged patients with still 
positive NPs. Secondly, our data could add further 
evidence in favour of switching to heparins from oral 
anticoagulants [21]. Thirdly, pharmacology research 
should be urged to design new heparin-derived mol-
ecules with expanded proportions of low-affinity 
chains, which most likely contribute to the alterna-
tive properties of heparins [7]. Lastly, considering 
that antiviral and immune-modulating mechanisms 
of LMWH potentially may act transversely across the 
Coronaviridae family [1,4,8], further confirmations 
to our preliminary data may guide clinical and public 
health decision making in the current pandemic and 
in its recrudescence, as well as in outbreaks of future 
emerging coronaviruses.
In conclusion, early prophylactic doses of LMWH 
in COVID-19 patients in a sub-intensive ward asso-
ciated with a significantly shorter time to NPs viral 
undetectability compared with delayed administra-
tion; other exploratory benefits of early LMWH 
administration were observed but need to be con-
firmed prospectively.
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